Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
07:00am, Friday, 17'th Oct 2025
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic Inflam
Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
07:00am, Thursday, 16'th Oct 2025
—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— —Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression in
Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
07:00am, Wednesday, 15'th Oct 2025
BRIDGEWATER, N.J. , Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality
02:33pm, Tuesday, 30'th Sep 2025
Insmed remains a compelling biotech trade after Brinsupri's FDA approval for NCFB, with strong de-risking and significant market potential. Brinsupri's aggressive pricing and broad label could drive p
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
07:00am, Monday, 22'nd Sep 2025
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session — —New Analysis from Phase
Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
12:10pm, Wednesday, 10'th Sep 2025
Insmed Incorporated (NASDAQ:INSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants William Lewis - President, CEO & Chairman Conference Call
Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
10:49am, Friday, 05'th Sep 2025
Insmed Incorporated (NASDAQ:INSM ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Partici
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Friday, 05'th Sep 2025
BRIDGEWATER, N.J. , Sept. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfo
Insmed To Present at September Investor Conferences
07:00am, Thursday, 21'st Aug 2025
BRIDGEWATER, N.J. , Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
02:46pm, Wednesday, 20'th Aug 2025
William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.
Josh Brown's Best Stocks in the Market: Insmed
01:04pm, Tuesday, 19'th Aug 2025
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.
Insmed price target raised to $145 from $121 at Stifel
11:33am, Thursday, 14'th Aug 2025
Stifel raised the firm's price target on Insmed to $145 from $121 and keeps a Buy rating on the shares following FDA's recent approval of Brinsupri as the first approved therapy for treatment of non-C
Insmed CEO on what's next for company after FDA greenlights lung disease drug
06:15pm, Wednesday, 13'th Aug 2025
Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
02:20pm, Tuesday, 12'th Aug 2025
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis
US FDA approves Insmed's lung disease drug
11:42am, Tuesday, 12'th Aug 2025
The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.
